ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia (AML). However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies in AML are negligible except for those targeting mutant isocitrate dehydrog...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Zhou, Jianbiao, Quah, Jessie Yiying, Ng, Yvonne, Chooi, Jing-Yuan, Toh, Sabrina Hui-Min, Lin, Baohong, Tan, Tuan Zea, Hosoi, Hiroki, Osato, Motomi, Seet, Qihui, Ooi, A.G. Lisa, Lindmark, Bertil, McHale, Mark, Chng, Wee-Joo
Format: Artigo
Idioma:Inglês
Publicat: Fondazione Ferrata Storti 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556493/
https://ncbi.nlm.nih.gov/pubmed/33054053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.230482
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars